AnaptysBio Stock Price - ANAB

0.13 (0.93%)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
AnaptysBio Inc ANAB NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.14 -0.99% 14.00 13.775 14.35 14.12 14.14 16:19:02
Bid Price Ask Price Spread Spread % News
13.50 15.00 1.50 10.0% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
6,228 391,542 $ 14.09 $ 5,514,870 713,550 9.16 - 83.10
Last Trade Time Type Quantity Stock Price Currency
16:00:17 683 $ 14.13 USD

AnaptysBio Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 383.49M 27.27M $ -61.66M -3.61 - 26.78M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

AnaptysBio News

Loading Messages....

Latest ANAB Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ANAB Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week13.3215.0812.8813.96614,3480.685.11%
1 Month17.1118.7012.0614.70624,046-3.11-18.18%
3 Months15.1418.7011.9515.06564,990-1.14-7.53%
6 Months35.2139.489.1615.27752,146-21.21-60.24%
1 Year73.5783.109.1626.53516,056-59.57-80.97%
3 Years29.17134.009.1653.31375,352-15.17-52.01%
5 Years16.00134.009.1652.46363,809-2.00-12.5%

AnaptysBio Description

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.